AstraZeneca and Daiichi Sankyo’s Enhertu has been approved in the European Union as monotherapy for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen, the company announced.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on AZN:
- AstraZeneca, Daiichi Sankyo announce Enhertu recommended for approval in the EU
- AstraZeneca price target raised to 13,000 GBp from 12,000 GBp at Deutsche Bank
- Merck, AstraZeneca: FDA to extend PDUFA date for sNDA for LYNPARZA combo
- AstraZeneca’s anifrolumab receives FDA orphan designation
- AstraZeneca says Dato-DXd ‘continued to demonstrate encouraging responses’